Antibiotic licensing studies remain a problem in neonates. The classical adult clinical syndrome-based licensing studies do not apply to neonates, where sepsis is the most common infection. The main obstacle to conducting neonatal antibiotic trials is a lack of consensus on the definition of neonatal sepsis itself and the selection of appropriate endpoints. This article describes the difficulties of the clinical and laboratory definitions of neonatal sepsis and reviews the varying designs of previous neonatal sepsis trials. The optimal design of future trials of new antibiotics will need to be based on pharmacokinetic/pharmacodynamic parameters, combined with adequately powered clinical studies to determine safety and efficacy.
Introduction
Neonatal sepsis is a serious condition; its clinical course can be rapid and result in death or significant long-term disabilities. However, the definition and diagnosis of sepsis in neonates are both difficult as clinical signs and laboratory markers are often nonspecific and indistinguishable from other conditions. 1 Hence, a large proportion of neonates and infants are treated for sepsis even though their blood cultures subsequently show no growth. 2 As clinical trials of antibiotics undertaken as a requirement for licensing for use in humans typically exclude neonates and children, we can identify no medicinal product recently authorized for the treatment of sepsis in neonates. The lack of clinical trial data also means that the optimal management of neonatal sepsis is still uncertain. Even recommendations from expert guidance documents such as the Manual of Childhood Infections: The Blue Book, 3 the British National Formulary for Children 4 or NeoFax 5 commonly vary for key questions such as indications for commencing and stopping antibiotics, the choice and dosing of antibiotics and the duration of therapy. There is also a paucity of data on the safety of antibiotics in this population. While there is a clear need for evidence-based recommendations for the treatment of neonatal sepsis, the design of appropriate clinical trials presents particular difficulties. A key problem remains the definition of sepsis, which is essential for specifying the inclusion criteria for recruitment of patients, but must also account for the large number of neonates with culture-negative sepsis, who may still have a bacterial infection (e.g. blood culture volumes in neonates may be very low). Equally challenging is the choice of feasible primary and secondary endpoints. This article highlights the difficulties of designing antibiotic trials by describing the high variability of past studies and discusses options for improving study design by using new technologies and definitions.
Sepsis definitions: sensitivity or specificity?
The aim of most studies investigating the predictors of serious infection in neonates is to aid clinicians in the rapid diagnosis of sepsis so that interventions may be started without delay. In clinical practice, empirical treatment with antibiotics is based on a highly sensitive scoring system. Inclusion criteria for trials of antibiotic efficacy, on the other hand, require higher specificity and must include objective, quantifiable parameters in order to monitor response to treatment and define resolution. This difficult problem led to a meeting in 2010, organized by the European Medicines Agency (EMA), to specifically address the lack of consensus on conducting clinical trials for evaluating medicinal products for paediatric and neonatal sepsis (http://www.ema.europa.eu/docs/ en_GB/document_library/Report/2010/12/WC500100199.pdf). A number of clinical and laboratory criteria for entry into a trial for neonates up to 44 weeks of post-menstrual age were agreed (Table 1) . For primary endpoints, composite outcomes were recommended and other possible primary endpoints were suggested. These parameters still require validation, which is one objective of a large ongoing European neonatal antibiotic trial (www.neomero.org). 6 
No recent neonatal antibiotic trials
Very few antibiotic efficacy trials in neonates have been conducted and these were mainly .20 years ago. Two Cochrane reviews have analysed the existing evidence to compare the effectiveness of antibiotic regimens for the treatment of early-onset sepsis (EOS) and late-onset sepsis (LOS). 7, 8 Thirteen studies were identified for the evaluation of LOS treatment and 15 for EOS. The studies chosen by both reviewers were almost identical; only one study was included in the final analysis for LOS and two for EOS, mainly because in the other studies the investigators did not differentiate between EOS and LOS. None of the selected studies met the criteria set for methodological quality in the reviews. We repeated the searches used by the Cochrane reviews using the same search strategies and, apart from one, 9 we could not identify any new trials published since the Cochrane review. Accordingly, we analysed the methods used in the trials selected by either review in more detail, along with the study by Metsvaht et al. 9 For the purposes of this review, we excluded 3 studies (1 study 10 was in French and 2 studies 11, 12 only evaluated safety) and scrutinized the 15 remaining antibiotics trials for EOS and LOS. This analysis informs a discussion of strategies to improve trial design. We note that most of the studies reviewed here are studies of effectiveness or comparative studies aiming to optimize treatment. While these approaches are useful, they can only be done once efficacy has been demonstrated. Nevertheless, effectiveness or comparator 
Clinical inclusion criteria
The inclusion criteria were not clearly defined in most of the reviewed studies. The decision on criteria defining suspected or proven sepsis was mostly the subjective opinion of the clinician, as shown in Table 2 . One study introduced a scoring system consisting of clinical and laboratory markers. 13 Clinical signs of sepsis are difficult to evaluate in adults and children, but are even more non-specific in neonates. Those most commonly evaluated in previous studies include abnormal body temperature, heart rate and peripheral perfusion, signs of respiratory distress, gastrointestinal signs and other general, non-specific signs. Most of these clinical signs are difficult to quantify and the changing normal values of the developing babies' physiology only adds to the complexity. In the few trials describing values in an objectively quantifiable way, there were differences between studies. Most studies also include different subpopulations of neonates, such as those with EOS and LOS, premature babies and term babies. Normal ranges for physiological variables vary markedly in these groups.
Evidence supporting reference ranges for commonly used laboratory markers of infection such as C-reactive protein (CRP) and total white blood cells (WBC) is limited.
14 No laboratory test or clinical sign in isolation currently accurately identifies neonatal infection. Predictive scoring systems such as the NOSEP (nosocomial sepsis) score, 15 as well as disease severity and organ dysfunction scores such as CRIB (Clinical Risk Index for Babies), 16 SNAP (Score for Neonatal Acute Physiology) 17 and Neomod (neonatal multiple organ dysfunction), 18 combine clinical signs, laboratory markers and risk factors for more comprehensive assessment. Organ dysfunction scores are of particular interest as potential surrogate outcomes for mortality that might therefore allow smaller clinical trials. However, an important potential limitation of a multiple organ dysfunction score is that a treatment may not change all the components of the score in the same direction and the results may be inconclusive. Composite scores, when used as inclusion criteria, need to be validated (internally and externally) and qualified (positive predictive value). However, this has not been achieved in neonates to date. Inconsistent effects of the treatment on the elements of the composite will reduce the precision of the score. This can be accounted for in study planning (i.e. larger sample size to account for imprecisions based on pilot data) and analysis. For example, in a regulatory setting, the analysis of all participants on an intention-to-treat basis can be supplemented with pre-planned analyses on specified subsets of evaluable participants. However, the implications of this standard approach to antibiotic efficacy for sample size and recruitment have not been identified in neonates.
Neomero is a currently ongoing antibiotic trial evaluating meropenem for the treatment of probable or proven neonatal sepsis and meningitis. In this trial, the inclusion criteria for patients with probable infection are based on the criteria defined by the International Pediatric Sepsis Consensus Conference for subjects older than 44 weeks post-menstrual age. 19 For subjects less than 44 weeks post-menstrual age, inclusion criteria agreed at the Expert Meeting on Neonatal and Paediatric Sepsis are applied. These consist of a combination of at least two abnormal clinical and laboratory parameters. 6 Prospective evaluation of the inclusion criteria is built into the study design, so that this study will clarify some of the important issues in the design of neonatal infection studies.
Microbiological criteria
Up to 80% of infants are treated for sepsis even though their blood cultures never grew an organism 2 and antibiotic treatment is usually started before culture results become available. Therefore, antibiotic trials must recruit infants with probable (clinical) infection. The high proportion of culture-negative cases of sepsis may be due to low levels of bacteraemia or that only small volumes of blood can be taken from sick infants. Alternatively, many neonates treated with antibiotics might not have an infection. Antibiotic treatment is often started because of common events that are not specific for infection. 20 Many infants have already been partially treated when blood cultures are taken, or fastidious or unknown bacteria that do not grow in conventional blood culture media could be the cause of infection. Microbiological eradication as an endpoint determined by bacterial blood culture alone will therefore fail to adequately describe the outcome of a significant proportion of trial subjects.
All reviewed studies performed blood cultures at trial entry and most also collected cultures from other sterile (CSF, suprapubic aspiration/catheter urine) and non-sterile sites. Two studies only included babies with definite sepsis, proven by a positive blood culture. 21, 22 Nine studies specifically indicated that positive cultures should be repeated during the course of the study. Two of those 21, 22 attempted to perform recultures daily until they became negative. One study 23 required a repeat culture to be done 5 days after the end of therapy, whilst others 9,24 specified reculturing when clinically indicated or did not provide defined intervals. Other studies 25 -27 reported microbiological eradication as an endpoint without clearly specifying their practice of repeating cultures.
Molecular methods such as PCR may overcome the diagnostic difficulties described above; however, sepsis can be caused by a large variety of pathogens, especially in LOS. Even multiplex PCRs targeting multiple pathogens or microarrays are limited to prechosen pathogens, a choice that is normally based on previous culture results. Bacterial broad-range PCRs targeting universal components of bacteria, such as 16S rDNA, can detect all bacteria, including unknown ones, but have been shown to lack the sensitivity of organism-specific PCRs and are prone to contamination. 28 Microbiology assessments should include both culture and molecular techniques, such as specific PCRs and broad-range assays, to improve sensitivity and the detection of pathogens that are difficult to culture. Ideally, all of these markers should be validated and qualified before being required elements of trials included in drug development programmes.
Combining clinical and laboratory parameters
In the majority of studies, an assessment of improvement was performed after 48 -72 h to decide if treatment would be continued. In five studies, clinical signs were recorded at regular intervals. The clinical and laboratory markers used to assess response to Tables 3 and 4 . In several studies, only broad terms such as 'non-specific deterioration in conjunction with laboratory markers', 'clinical manifestations of sepsis' and 'direct or indirect indicators of sepsis' were used. 23, 29, 33 Only Wiese 13 used the scoring scale employed at enrolment in order to quantify improvement.
To allow an objective, quantifiable measurement of improvement, assessments for specific clinical signs and laboratory parameters at pre-specified timepoints should be graded and compared with those at baseline. 6 
Pharmacokinetic (PK) analysis
Nine studies included a PK analysis. Blood levels at peak and trough were obtained in all of those nine studies, apart from one that collected mean levels. Two of the nine studies did not relate their PK data to pharmacodynamic (PD) results (e.g. susceptibility of the microorganism). MIC values were either obtained from local testing or from the literature (see Table 5 ).
The physiological processes that influence absorption, distribution, metabolism and excretion are immature and develop throughout the neonatal period. Reviews of PK studies of antibiotics in neonates also show that there is very significant interindividual variability between premature and more mature infants, which need to be considered. Due to reduced renal excretory function, the clearance of cephalosporins, 30 aminoglycosides 31 and penicillins 32 is reduced in premature and, to a lesser extent, in term infants.
Primary endpoints
Clear test-of-cure endpoints were often not described in these older trials, but can be deduced from the reported results. Primary endpoints were mostly defined as subjective clinical cure and/or improvement and bacteriological eradication, as described in Table 5 . The one study that used a composite scoring system 13 did not further define these markers, resulting in a subjective judgement. This is of further concern, as none of the studies were blinded. Death was reported as failure by all studies. Most of the studies did not report a time interval between death and infection or specified either all-cause mortality or death due to infection. Failure of treatment was otherwise defined as modification of treatment, no response to treatment or resistance. Superinfection and relapses were reported by three studies.
Trial design issues
Other important factors such as the sample size calculation and a description of the demographics of the recruited population are often not reported. The sample sizes of the reported studies were small, with only five having enrolled .100 participants. Of these five, only two mentioned any power calculations: de Louvois et al. 33 described their trial as 'large enough to give accurate data on efficacy', but did not provide further details, whilst Metsvaht et al. 9 reported appropriate sample size calculations based on a retrospective analysis of medical records.
Data recorded on participants varied widely in content and detail. Most significantly, often no clear distinction between EOS and LOS was made, even though they differ significantly in aetiology, range of pathogens and outcome. 34 The age of participants was often reported as 'neonates' or 'infants' only, recorded upper age limits ranged from ,45 days to 3 months. Four studies report outcomes for EOS alone or separately, but definitions of EOS varied, ranging from ,48 h to ≤7 days of life 27, 35, 36 and only one study used the recent consensus definition of EOS (,72 h of life). 9 Two studies compared antibiotics in babies with LOS, using . 48 h as the definition. 22, 35 The majority of studies give details of only gestational age, sex and birth weight and often do not include all of these parameters. Six studies also categorized infants according to the severity of their clinical status at study entry (see Table 2 ). 9,21 -23,33,36 Exclusion criteria also varied between the trials. Previous antibiotic use was an exclusion criterion in 7 of the 15 selected trials, though the prohibited time span of antibiotics given prior to enrolment varied from 24 to 72 h or was not specified. Other exclusion criteria are listed in Table 6 .
Discussion
Any antibiotic efficacy trial, including those conducted in neonates, needs specific inclusion criteria and also objective, quantifiable parameters to monitor response to treatment and to define resolution. Currently, the EMA consensus document has a limited evidence-based definition of neonatal sepsis. No composite scoring system for trial entry or clinical response in antibiotic treatment neonatal sepsis studies has yet been validated or qualified. The choice of the most appropriate endpoints also remains an issue. Death is a difficult primary endpoint, as the cause of death in the critically ill neonate with sepsis often cannot clearly be attributed solely to infection as opposed to underlying disease. If all-cause mortality was used as an endpoint, other common causes of death, such as withdrawal of intensive care, would distort the results. Therefore, a composite endpoint including clinical and laboratory parameters seems to be the most appropriate primary endpoint. Other possible endpoints, such as the need to change the antibiotic regimen, clinical cure defined as the complete resolution of clinical signs, return to baseline status or no requirement for further antibacterial therapy, could all be evaluated in future studies. 37 New combination biomarkers may be helpful in the future, both to aid in the diagnosis of bacterial sepsis and to monitor the PD response to treatment. Extensive research has been undertaken to evaluate numerous biomarkers over the last 20 years; however, apart from CRP and procalcitonin (PCT), none is currently widely used in clinical and research settings. New advanced technologies, such as transcriptomics, which examines the gene expression changes in the host that accompany infection, have progressed research on novel host response biomarkers. Protein microarrays are also increasingly used in infectious disease research to study complex proteomes and have the potential to identify new biomarker combinations to determine sepsis responses. 38, 39 However, none of these methods has been validated or qualified sufficiently well to be required elements of clinical trials.
PK/PD analyses provide important information on the antimicrobial effect of an agent. Population-based methods allow a description of the variability in PK parameters and their dependence on patient characteristics and therefore can establish individualized dose regimens based on patient-specific covariates. Population PK parameters can be estimated with only a few samples collected from each patient. This approach allows quantification and prediction of how the variability of the drug plasma concentration acts on the variability of the drug effect, which then enables the optimization of dosage regimens. Population PK is used extensively for Phase II and III studies and to summarize data across drug development programmes. 40 However, there are still uncertainties about which targets and target values are the most appropriate for neonatal studies. It should also be noted that compared with the bactericidal effect of an antimicrobial agent, significantly higher PD targets may be required for the suppression of resistance. Several target values, such as C max / MIC (peak concentration-to-MIC ratio) for aminoglycosides, %T .MIC (the percentage of time that the free drug concentration remains above MIC) for b-lactams, AUC/MIC (the area under the serum concentration curve to MIC ratio) of .400 for vancomycin, have been proposed for critically ill adults. These targets may be appropriate for neonates, but more studies and simulations are required for evaluation. 6 Premature neonates have impaired immune responses and from a PK/PD perspective may be considered as an immunocompromised host. Equally, most PD markers for safety assessment have not been adequately validated in neonates yet either, so there are clear limitations and concerns where drug development programmes rely on PK/PD studies alone.
The recently updated 'Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections' suggests that results of PK studies can provide supportive information on the efficacy of an antibiotic in some circumstances. A draft Addendum to the Guidance notes that it may be possible to support an indication for an antibacterial agent in the treatment of bacteraemia without restriction to certain pathogens, which could potentially include neonatal sepsis (see http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2012/07/WC500129443. pdf). Because of all the difficulties with sepsis definitions and outcomes in adults, marketing authorization studies for bacteraemia have so far not been taken forward by regulators.
Research tools for PK/PD studies (e.g. population PK, populationspecific 'biomarkers') adapted to newborns and infants are being developed, while improved sampling techniques (e.g. saliva samples) and more accurate quantification of metabolites in lowvolume samples increase the feasibility of conducting clinical trials in neonates. 41 Given the difficulties and imprecise nature of evaluating a clinical response to antibiotics for sepsis at any age, modelling and simulation based on targeted PK/PD endpoints combined with safety parameters as the principal assessment for validation of both new and older antibiotics may be a more efficient and less time and cost intensive way to improve our woefully inadequate knowledge base for antibiotic prescribing in neonates. 42 We have outlined suggestions for the key criteria to be considered in the design of new neonatal sepsis trials in Table 7 .
Research implications
Research is needed to underpin future trials. This includes the prospective validation and qualification of inclusion criteria (clinical, microbiological and laboratory). These evaluations need to be done in clinical trial settings, because results from cohort or case-control studies may not be generalizable to the babies who are recruited to clinical trials. Further research is also needed on the differences between neonates, children and adults in the PK/PD relationship to clinical outcome. The implementation of a Limited Population Antibacterial Drug Approval Mechanism is currently being discussed in the USA. This new approval pathway is intended for antibacterial drugs against serious infections where insufficient therapeutic options exist. The safety and effectiveness of drugs indicated for use in well-defined populations would be studied in substantially smaller, more rapid and less expensive clinical trials (see http://www.idsociety.org/uploadedFiles/IDSA/ News_and_Publications/IDSA_News_Releases/2012/LPAD%20one% 20pager.pdf#search¼%22lpad%22). antibiotics in previous 24 h not specified not specified not specified
Nelson, 26 1973 not specified meningitis, congenital syphilis not specified not specified Odio, 21 1987 not specified underlying hepatic or renal disease not specified suspected or proven infection with organism resistant to study drugs, cultures negative Snelling, 27 1983 not specified not specified not specified not specified Tessin, 44 1989 not specified not specified not specified not specified Umana, 22 1990 not specified suspected or confirmed hepatic or renal dysfunction (based on ALT, urea, creatinine) not specified infection with organism resistant to study treatment, cultures negative Wiese, 13 1988 not specified not specified not specified not specified
The lack of an approval of antibiotics in adults for a sepsis indication makes direct extrapolation to neonatal sepsis difficult. Only a few older antibiotics are approved for the treatment of sepsis in adults, making extrapolation to neonates difficult.
Summary
Regulators and sponsors, working with investigators, need to define a pragmatic approach to study design, including decisions on what are sufficient data to provide adequate prescribing information. For new antibiotics, if the disease processes are thought to be the same in neonates and adults, trials based on PK and safety are considered by regulators to be adequate. This will include antibiotics for infections that are not commonly seen in neonates or for rapid assessment of novel, or legacy, agents against resistant organisms. Detailed formal post-marketing surveillance plans are really important to develop our understanding of safety and PK. This approach could also be relevant for antibiotics with a low risk of misclassifying efficacy, e.g. antibiotics that are well known as being active against common infections in neonates (i.e. Group B streptococcus or Escherichia coli). Sponsors may require a more detailed understanding of whether the bug (e.g. MIC) or the host response (i.e. the appropriate PD endpoint) is the same in neonates as in children or adults.
The risk with all these approaches is that PK/PD studies alone will not predict outcome. This risk can be mitigated by pre-planned analyses of different evaluable populations and different outcome assessments. Where outcomes vary in their response to a similar drug exposure (e.g. between laboratory and clinical data), sponsors and regulators will need to clarify their views on an assessment of efficacy based on exposure alone. Large and expensive formal studies of efficacy will probably rarely be conducted (there have been none in the last 20 years!) and require a number of conditions to be met. The comparators must each be adequately dosed (PK/PD effects must be similar, to avoid confounders such as suboptimal dosing in one arm). There needs to be an evidencebased justification for sample size (either superiority or, more commonly, non-inferiority) and it should be feasible to recruit enough babies for the evaluation of the primary outcome. However, these trials may still not give a definitive answer due to hidden bias, or lack of power, or lack of effect. This approach will have economic and opportunity costs (i.e. all the other simpler and cheaper studies that are not done instead), which need to be justified according to the importance of having direct efficacy data and not inferring efficacy from other approaches. An efficacy trial may be justified if there is a high risk of an agent not having activity against key bacteria that infect neonates. Efficacy trials should not be confused with effectiveness trials or trials that seek to define optimal therapy. Effectiveness or optimization trials require different approaches, may be more pragmatic and may appropriately be done after a marketing authorization is in place for neonates.
All clinical trials in neonates should be able to influence marketing authorizations if the results are relevant to the prescribing information. Accordingly, the stringency required for regulatory trials 
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should be found in all trials, whether they are publically funded or sponsored by industry. Regulators, sponsors and investigators need to make some difficult judgements on the prescribing of antibiotics for neonates. As described above, we advocate a reasonable stepped approach based on the consequences of misclassifying an antibiotic as efficacious when it is not.
